Gemcitabine fixed-dose rate infusion for the treatment of pancreatic carcinoma: a meta-analysis of randomized controlled trials by unknown
Xie et al. Diagnostic Pathology 2014, 9:214
http://www.diagnosticpathology.org/content/9/1/214RESEARCH Open AccessGemcitabine fixed-dose rate infusion for the
treatment of pancreatic carcinoma: a
meta-analysis of randomized controlled trials
Jiqing Xie1†, Jing Yuan2† and Laichun Lu3*Abstract
Background: Pre-clinical evidence shows that fixed dose rate (FDR) infusion of gemcitabine could optimize plasma
concentration of gemcitabine, while the clinical efficacy and toxicity of FDR infusion of gemcitabine in advanced
pancreatic carcinoma has not been systematically investigated. Thus, this meta-analysis was designed to ascertain
this issue.
Methods: Databases of EMBASE, PubMed, and Cochrane Library were searched for eligible randomized controlled
trials (RCTs). RCTs comparing FDR and standard 30-min infusion of gemcitabine in advanced pancreatic carcinoma
were included. The primary endpoints were treatment efficacy (overall response rate, 1-year survival rate, median
survival, and time to treatment failure) and toxicities were secondary endpoints (neutropenia, thrombocytopenia,
anemia, and vomiting). Relative risks or mean differences and corresponding 95% confidence intervals (CIs) were
calculated.
Result: After careful and rigorous selection, 3 eligible RCTs including 764 patients of advanced pancreatic
adenocarcinoma were included in this meta-analysis. For treatment efficacy, FDR gemcitabine provided significantly
longer median survival over standard gemcitabine (Mean Difference = 1.24 months, 95% CI: 0.39-2.09), while there
was no statistical difference in other endpoints of treatment efficacy. For toxicities, patients with FDR gemcitabine
experienced significantly more grade 3/4 hematological toxicities than those received standard gemcitabine
(neutropenia, thrombocytopenia, and anemia), while there was no difference for vomiting.
Conclusion: Compared with standard 30-min infusion, FDR gemcitabine provide longer median survival, but
increased the risk of hematological toxicities for patients with advanced pancreatic adenocarcinoma.
Virtual Slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/
vs/13000_2014_214
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Pancreatic adenocarcinoma is one of the most aggressive
solid malignancies and the eighth most common cause
of cancer death worldwide [1]. Due to early metastatic
dissemination, the prognosis of pancreatic adenocarcin-
oma is extremely poor and the 5-year survival rate is
only 6% [2].* Correspondence: laichun_lu@126.com
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unless otherwise stated.The majority of pancreatic adenocarcinoma patients
are diagnosed at advanced stage and when diagnosed,
the tumor is often metastasized. Therefore, systemic
chemotherapy is often the treatment of choice. The ad-
ministration of gemcitabine is widely used due to the
evidence of clinical benefit and prolonged survival over
fluorouracil [3]. While the objective response rate and
survival of gemcitabine chemotherapy is still disappoint-
ing. Gemcitabine is usually administered in a manner of
30 minutes intravenous infusion, while pharmacokinetic
evidence suggests that fixed-dose rate infusion (10 mg/m2/
min) of gemcitabine could optimize plasma concentration. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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gemcitabine could not improve survival or response rate
over standard gemcitabine in non-small cell lung cancer
[7]. For pancreatic adenocarcinoma, FDR gemcitabine and
standard gemcitabine have been compared in several ran-
domized clinical trials (RCTs) [8-10], but no meta-analysis
has been performed to systematically investigate the effects
of FDR gemcitabine on treatment efficacy or toxicity. Thus,
this meta-analysis was designed to compare the difference
between FDR gemcitabine and standard gemcitabine in the




Electronic databases of MEDLINE (via PubMed), EMBASE
(via Ovid), and Cochrane Library were searched and the
latest search was performed on September 2014. The
searching strategy consisted of the following medical
subheadings and key words: “pancreatic neoplasms”, “pan-
creas cancer”, “pancreatic cancer”, “fixed-dose rate”, “fixed
dose rate”, “fixed-dose-rate”, “fixed dose-rate”, “prolonged
infusion” and “prolonged constant infusion”. The detailed
searching strategy was shown in the Additional file 1. Ref-
erences of eligible trials and relative reviews were also
manually searched. There was no limitation in databases
searching.
Inclusion criteria
Trials met the following criteria were included: (a) ran-
domized controlled trials; (b) patients were pathologically
confirmed of pancreatic carcinoma at advanced stage; (c)
comparing FDR infusion (10 mg/m2/min) and standard
infusion (30 min) of gemcitabine; and (d) published with
full-text articles. Two investigators (Jiqing Xie and Jing
Yuan) selected eligible trials met above criteria independ-
ently. Disagreement between two investigators was solved
by discussion until consensus was achieved.
Data abstraction
Two investigators (Jiqing Xie and Jing Yuan) extracted
data from eligible trials independently with a pre-designed
data extraction form. And disagreement was discussed
with another expert (Laichun Lu) until consensus was
achieved. The following data were abstracted from each
eligible clinical trial: first author, publishing time, country,
chemotherapy regimens, number of patients, age, number
of male, number of patients with metastatic pancreatic
carcinoma, number of patients with complete response
and partial response, 1-year survival rate, median survival,
time to treatment failure, grade 3/4 hematological and
non-hematological toxicities. Tumor response was mea-
sured according to Response Evaluation Criteria in Solid
Tumors (RECIST). National Cancer Institute CommonToxicity Criteria version 3.0 was used for toxicity report-
ing. The research protocol was in strict compliance with
the institutional guidelines of the Ethics Committee at the
Third Military Medical University.
Validity assessment
Methodology quality of included trials was also assessed
using the “risk of bias” tool recommended by Cochrane
Handbook V5.0.2. Sequence generation, allocation con-
cealment, blinding, incomplete data and selective report-
ing were assessed. Based on the methods reported in each
trial, each of above five components was graded “yes”, “un-
known” or ”no”, which meant low risk of bias, uncertain
of bias and low risk of bias respectively.
Statistical analysis
The primary endpoints were treatment efficacy (overall re-
sponse rate, 1-year survival rate, median survival, and time
to treatment failure) and toxicities were secondary end-
points (neutropenia, thrombocytopenia, anemia, and vomit-
ing). Mean differences were calculated for median survival
and time to treatment failure. Relative risks (RRs) were cal-
culated for the other endpoints. 95% confidence intervals
(95% CI) were also calculated for all endpoints. A RR with
a 95% CI without 1 and the mean difference with a 95% CI
without 0 is considered of statistical significance. Fixed-
effects model was used for calculating RRs and median dif-
ferences unless heterogeneity was significant across trials
[11]. A RR >1 indicates that FDR infusion is associated with
a higher incidence of response, 1-year survival rate and
lower incidence of grade 3/4 toxicities; and a mean differ-
ence >0 suggests that the FDR infusion of gemcitabine in-
creases the median survival and time to treatment failure.
Heterogeneity was tested using the Q-statistic and I2. A P
value less than 0.1 or I2 > 50% indicated that there existed
significant heterogeneity [11]. A funnel plot was used to test
publication bias [12,13]. All statistical analyses were carried
out by Review Manager 5 (Version 5.2, The Cochrane
Collaboration).
Results
After comprehensive database searching, 216 records
were retrieved. By screening titles and abstracts and fur-
ther reviewing of full-text papers, 3 eligible RCTs were
included and analyzed in this meta-analysis. The process
of study selection was shown in Figure 1. The baseline
characteristics of eligible trials were shown in Table 1.
764 patients with confirmed pancreatic adenocarcinoma
contributed to the pooled meta-analysis. Most of en-
rolled patients had metastatic pancreatic carcinoma.
Primary endpoints
The primary object of this meta-analysis was to com-
pare the differences of treatment efficacy between FDR
Figure 1 Flow Diagram of Study Selection.
Table 2 Meta-analysis results
Outcome RRa Heterogeneity
Primary Endpoints
Overall response rate 1.65 [0.99, 2.75] P = 0.45, I2 = 0%
1-year survival rate 1.35 [0.98, 1.86] P = 0.12,I2 = 59%
Median Survival 1.24 [0.39, 2.09]b P = 0.42,I2 = 0%
Time to Treatment Failure 0.54 [0.25, 1.33]b P = 0.22,I2 = 33%
Secondary Endpoints
Neutropenia 1.79 [1.49, 2.15] P = 0.92,I2 = 0%
Thrombocytopenia 2.19 [1.64, 2.93] P = 0.50,I2 = 0%
Anemia 1.68 [1.15, 2.45] P = 0.45,I2 = 0%
Vomiting 1.31 [0.89, 1.93] P = 0.79,I2 = 0%
a: RR with a 95% CI without 1 and the mean difference with a 95% CI without
0 is considered of statistical significance; b: for median survival and time to
treatment failure, mean differences were calcluated.
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calculated the pooled 1-year survival rate, median sur-
vival, and overall response rate. As shown in Table 2,
FDR gemcitabine provided a significantly long median
survival (Mean Difference = 1.24 months, 95% CI: 0.39-
2.09 months; Figure 2) than standard gemcitabine,
while there was no significant difference in overall re-
sponse rate, 1-year survival rate, or time to treatment
failure. As shown, no significant heterogeneity between
studies were detected. Visual assessment of funnel plot
did not reveal any evidence of publication bias (Figures
not shown).
Secondary endpoints
Grade 3/4 toxic events were the secondary endpoints of
this meta-analysis. Neutropenia, thrombocytopenia, anemia
and vomiting were analyzed. As shown in Table 2,
compared with standard gemcitabine, FDR gemcitabine
significantly increased the incidence of hematologic toxic-
ities (neutropenia, thrombocytopenia, and anemia; com-
passion of neutropenia was shown in Figure 3), while
there was no difference in the incidence of vomiting. As
shown in Table 2, no evidence of heterogeneity wasTable 1 Baseline characteristics of eligible trials
Author Year Country Numa Male Ageb
Kulke MH 2009 USA 58 38 58.9(31–81)
62 35 58.9(36–84)
Poplin E 2009 USA 277 160 61(36–87)
275 155 64(31–88)
Tempero M 2003 USA 43 27 62(42–85)
49 32 62(31–89)
a: Number of patients analyzed, b: data are present as median and range.found. Funnel plots also showed no publication bias
(Figures not shown).
Discussion
In this meta-analysis, we found FDR gemcitabine, com-
pared with standard gemcitabine, could provide longer
median survival for patients with advanced pancreatic
carcinoma, and patients received FDR gemcitabine would
experience more hematological toxicities.
Burris HA and colleagues reported in 1997 that single-
agent gemcitabine administered as weekly 30-min infusion
could offer significantly longer survival and clinical benefit
than 5-fluorouracil [3]. After that gemcitabine has been the
standard chemotherapy for advancer pancreatic carcinoma.
Gemcitabine (2’,2’-difluorodeoxycytidine) is a prodrug and
potent cytotoxic agent. The deoxycytidine kinase phos-
phorylate gemcitabine to gemcitabine monophosphate,
and subsequent phosphorylation steps yielded gemcitabine
diphosphate and gemcitabine triphosphate, which are
active metabolites of gemcitabine [4,14]. The gemcitabineMetastasis Chemotherapy
58 gemcitabine 1500 mg/m2 infusion 10 mg/m2/min
on days 1, 8, and 15, every 28 days
62 gemcitabine 1000 mg/m2 30-minute infusion d1, 8,
and 15;Cisplatin 50 mg/m2 30-minutes infusion on
days 1 and 15, every 28 days
246 gemcitabine 1500 mg/m2 infusion at 10
mg/m2/min days 1, 8, and 15 every 28 days cycle
248 gemcitabine 1000 mg/m2/30 min weekly for 7 week,
rest 1 week, then 1000 mg/m2/30 min weekly for 3
week and rest 1 week
38 gemcitabine 1500 mg/m2 infusion at a rate of 10
mg/m2/min, d1, 8, and 15
46 gemcitabine 2200 mg/m2 infusion over 30 min,
d1, 8, and 15
Figure 2 Forest plot for the comparison of median survival. FDR gemcitabine provided longer median survival than standard gemcitabine
(Mean Difference = 1.24 months, 95% CI: 0.39-2.09). FDR: fixed-dose rate; SD: standard deviation; CI: confidence intervals.
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apoptosis by incorporation into DNA [15,16]. The deo-
xycytidine kinase is the rate-limiting enzyme in the accu-
mulation of the active diphosphate and triphosphate
metabolites [4]. Grunewald et al. and Abbruzzese et al.
demonstrated that the dose rate about 10 mg/m2/min
could maximize the rate of formation of gemcitabine tri-
phosphate for mononuclear cells [4,6]. In addition to these
pharmacokinetic studies and preclinical studies, Tempero
et al. reported a randomized phase II trial in 2003 and
found FDR gemcitabine significantly increased 1-year and
2-year survival rates compared with 30-min gemcitabine
[10]. In 2009, Poplin and colleagues showed that FDR
gemcitabine could not provide substantially improved
survival or symptom benefit over 30-min gemcitabine [9].
Thus, we conducted this meta-analysis to compare the
treatment efficacy and toxicity between FDR gemcitabine
and 30-min gemcitabine in patients with advanced pan-
creatic adenocarcinoma.
In this meta-analysis, we found FDR gemcitabine could
only increase median survival of patients with pancreatic
adenocarcinoma over standard gemcitabine, and there was
no difference in overall response rate, 1-year survival rate,
or time to treatment failure. This could be explained by
the following reasons. First, the sample size or the number
of eligible trials of this meta-analysis was small. As shown
in Table 2, the results of overall response rate (RR = 1.65,
95% CI: 0.99-2.75) and 1-year survival rate (RR = 1.35, 95%
CI: 0.98-1.86) were marginally significant, and it was
highly possible that the results of response and 1-year sur-
vival would be statistically significant when further trials
are reported. Second, most patients enrolled in this meta-Figure 3 Forest plot for the comparison of neutropenia. FDR gemcitab
1.49-2.15). FDR: fixed-dose rate; CI: confidence intervals.analysis had metastatic disease (Table 1) and the prognosis
of metastatic pancreatic cancer is very poor. This could ex-
plain why the median survival was significantly longer for
patients received FDR gemcitabine but the 1-year survival
rate was not significantly different. Because the prognosis
for metastatistic patients was extremely poor and most pa-
tients died with one year. For toxicities, patients with FDR
gemcitabine experienced substantially higher incidence of
hematologic toxicities (neutropenia, thrombocytopenia,
and anemia) than those with 30-min gemcitabine, but
there was no difference in the incidence of vomiting. Com-
pared with 30-min gemcitabine, the infusion time was pro-
longed for FDR gemcitabine (120 min vs. 30 min), and the
exposure time for blood cells was longer. Thus, the results
for hematologic toxicities were expectable. Additionally, it
has also been demonstrated that FDR gemcitabine could
increase the incidence of hematologic toxicities in non-
small cell lung cancer by Qiu et al. [7].
This is the first meta-analysis comparing treatment
efficacy and toxicities between FDR gemcitabine and
standard 30-min gemcitabine in pancreatic adenocar-
cinoma. No significant heterogeneity was found and
funnel plots revealed no evidence of publication bias.
Additionally, the evidence level of this meta-analysis
was evaluated by the GRADE profiler, which facilitates
the clinical application of our results. On the other
hand, the major limitation of this meta-analysis lies in
that the sample size of this meta-analysis was small. To
include all potential trials, we designed comprehen-
sive searching strategy and searched the 3 compre-
hensive databases. In spite of the effort to perform a
comprehensive meta-analysis, only 3 eligible trialsine significantly increased the risk of neutropenia (RR = 1.79, 95% CI:
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our findings.
Conclusions
In conclusion, our meta-analysis demonstrated that com-
pared with standard 30-min gemcitabine, FDR gemcita-
bine provided longer median survival but there was no
significant difference in overall response rate and 1-year
survival rate in patients with advanced pancreatic adeno-
carcinoma, while FDR infusion was associated with more
grade 3/4 hematological toxicities.
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